Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cmi.2021.05.004 http://scihub22266oqcxt.onion/10.1016/j.cmi.2021.05.004 33975007!8106520!33975007     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Microbiol+Infect 2021 ; 27 (9): 1351.e5-1351.e7 Nephropedia Template TP {{tp|p=33975007|t=2021. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2) |pdf=|usr=}}{{33975007}} gab.com Text Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2) JO: Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=33975007 #FOAvip OBJECTIVES: Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimum dose regimen in this population has not been clearly studied. The CRO-VAX HCP study aims to investigate the early antibody response in a population of health-care professionals having received two doses of the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine. METHODS: The CRO-VAX HCP study is a multicentre, prospective, interventional study conducted in several sites in Belgium. The study included 231 health-care professional volunteers who received the two-dose regimen of the BNT162b2 mRNA COVID-19 vaccine. Of these, 73 were previously infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 158 were uninfected and seronegative. In the first group, blood samples were collected at baseline and after 2, 4, 7, 10, 14, 21 and 28 days. In the second group, samples were obtained at baseline and after 14 and 28 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time-points. RESULTS: In uninfected individuals, 95.5% (95% CI 91.0%-98.2%) developed anti-spike antibodies after 14 days and a 24.9-fold rise (95% CI 21.4%-28.9%) in antibody titre was observed after the second dose. In previously infected individuals, peak antibody response was reached after 7 days (i.e. 6347 U/mL) and the second dose did not lead to significantly higher antibody titres (i.e. 8856-11 911 U/mL). Antibody titres were higher in previously infected individuals. CONCLUSIONS: This study supports the concept that a single dose of BNT162b2 would be sufficient in previously infected individuals. Twit Text FOAVip Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2) ????Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=33975007 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33975007 #FOAvip English Wikipedia <ref>{{Cite pmid|33975007}}</ref> Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2) #MMPMID33975007 Favresse J; Bayart JL; Mullier F; Dogne JM; Closset M; Douxfils J Clin Microbiol Infect 2021[Sep]; 27 (9): 1351.e5-1351.e7 PMID33975007show ga OBJECTIVES: Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimum dose regimen in this population has not been clearly studied. The CRO-VAX HCP study aims to investigate the early antibody response in a population of health-care professionals having received two doses of the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine. METHODS: The CRO-VAX HCP study is a multicentre, prospective, interventional study conducted in several sites in Belgium. The study included 231 health-care professional volunteers who received the two-dose regimen of the BNT162b2 mRNA COVID-19 vaccine. Of these, 73 were previously infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 158 were uninfected and seronegative. In the first group, blood samples were collected at baseline and after 2, 4, 7, 10, 14, 21 and 28 days. In the second group, samples were obtained at baseline and after 14 and 28 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time-points. RESULTS: In uninfected individuals, 95.5% (95% CI 91.0%-98.2%) developed anti-spike antibodies after 14 days and a 24.9-fold rise (95% CI 21.4%-28.9%) in antibody titre was observed after the second dose. In previously infected individuals, peak antibody response was reached after 7 days (i.e. 6347 U/mL) and the second dose did not lead to significantly higher antibody titres (i.e. 8856-11 911 U/mL). Antibody titres were higher in previously infected individuals. CONCLUSIONS: This study supports the concept that a single dose of BNT162b2 would be sufficient in previously infected individuals. |Adult[MESH] |Aged[MESH] |Antibodies, Viral/*blood[MESH] |BNT162 Vaccine[MESH] |Belgium[MESH] |COVID-19 Vaccines/*administration & dosage/immunology[MESH] |COVID-19/*epidemiology/immunology/prevention & control[MESH] |Case-Control Studies[MESH] |Drug Administration Schedule[MESH] |Female[MESH] |Health Personnel[MESH] |Humans[MESH] |Immunity, Humoral[MESH] |Male[MESH] |Middle Aged[MESH] |Prospective Studies[MESH] |SARS-CoV-2/*immunology[MESH] |Spike Glycoprotein, Coronavirus/*immunology[MESH] |Time Factors[MESH]Early antibody response in health-care professionals after two doses o(epmc).pdf DeepDyve Pubget Overpricing